Q-linea AB

Q-linea AB is a Swedish infection diagnostics company founded in 2008, specializing in rapid antimicrobial susceptibility testing (AST) systems for sepsis and bloodstream infection management. The company's flagship product, ASTar, is a fully automated, CE-IVD marked system that delivers antibiotic susceptibility profiles directly from positive blood cultures in approximately six hours—significantly faster than traditional methods that require 48+ hours. ASTar operates with minimal hands-on time (less than two minutes) and provides accurate MIC (minimum inhibitory concentration) values through controlled inoculum protocols, integrating with electronic medical records for seamless laboratory workflows. Q-linea addresses a critical clinical need: sepsis affects approximately 50 million people globally each year with 11 million deaths, making rapid diagnosis and appropriate antibiotic selection essential for patient survival. The company holds CE-IVD approval in Europe and FDA 510(k) clearance in the US, and collaborates with partners like Thermo Fisher Scientific for product commercialization. Q-linea's mission focuses on improving sepsis treatment outcomes while reducing unnecessary antibiotic use and combating antimicrobial resistance.